- Home
- ALMS vs YMAB Comparison
ALMS vs YMAB Comparison
Compare ALMS & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALMS
- YMAB
- Stock Information
- Founded
- ALMS 2021
- YMAB 2015
- Country
- ALMS United States
- YMAB United States
- Employees
- ALMS N/A
- YMAB N/A
- Industry
- ALMS
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ALMS
- YMAB Health Care
- Exchange
- ALMS NYSE
- YMAB Nasdaq
- Market Cap
- ALMS 652.3M
- YMAB 631.1M
- IPO Year
- ALMS 2024
- YMAB 2018
- Fundamental
- Price
- ALMS $9.44
- YMAB $10.10
- Analyst Decision
- ALMS Strong Buy
- YMAB Strong Buy
- Analyst Count
- ALMS 6
- YMAB 9
- Target Price
- ALMS $29.60
- YMAB $21.56
- AVG Volume (30 Days)
- ALMS 90.9K
- YMAB 274.1K
- Earning Date
- ALMS 11-13-2024
- YMAB 11-08-2024
- Dividend Yield
- ALMS N/A
- YMAB N/A
- EPS Growth
- ALMS N/A
- YMAB N/A
- EPS
- ALMS N/A
- YMAB N/A
- Revenue
- ALMS N/A
- YMAB $84,553,000.00
- Revenue This Year
- ALMS N/A
- YMAB $10.24
- Revenue Next Year
- ALMS N/A
- YMAB $20.21
- P/E Ratio
- ALMS N/A
- YMAB N/A
- Revenue Growth
- ALMS N/A
- YMAB N/A
- 52 Week Low
- ALMS $8.23
- YMAB $5.29
- 52 Week High
- ALMS $13.53
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- ALMS N/A
- YMAB 21.95
- Support Level
- ALMS N/A
- YMAB $12.47
- Resistance Level
- ALMS N/A
- YMAB $11.11
- Average True Range (ATR)
- ALMS 0.00
- YMAB 1.05
- MACD
- ALMS 0.00
- YMAB -0.52
- Stochastic Oscillator
- ALMS 0.00
- YMAB 4.04
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.